Talon Therapeutics, Inc. Announces Enrollment and Dosing of the First Patient in the Phase 3 Confirmatory Study of Marqibo(R) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia (HALLMARQ Study)
SAN MATEO, Calif., June 1, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON - News) announced enrollment and dosing of the first patient in the Phase 3 confirmatory study of Marqibo(R) (vincristine sulfate liposome injection) in adults (60 years of age and older) with newly diagnosed Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL), known as the HALLMARQ Study.